Related Experiment Video
Updated: Apr 8, 2026

06:46
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
Published on: December 14, 2020
3.5K
[Risk-benefit of anti-reflux therapy in the premature infant]
1Unité de gastroenterologie pédiatrique, CHU de Rouen, Université de Sherbrooke, Département de pédiatrie, Hôpital Charles Nicolle, 76031 Rouen cedex, France.
Abstract
No abstract available in PubMed .
Related Concept Videos
Gastroesophageal Reflux Disease II: Clinical Features and Management
1.2K
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
786
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
786
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
73
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
73

